 | Up a level |
Sebastian, Tim; Barco, Stefano; Voci, Davide; Lichtenberg, Michael; Schlager, Oliver; Jalaie, Houman; de Graaf, Rick; Erbel, Christian; Massmann, Alexander; Schindewolf, Marc; Spirk, David (2024). The TOPOS study. Vasa - European journal of vascular medicine, 53(3), pp. 217-224. Huber 10.1024/0301-1526/a001118
Wortmann, Julian Kleine; Barco, Stefano; Fumagalli, Riccardo M; Voci, Davide; Hügel, Ulrike; Cola, Rahel; Spirk, David; Kucher, Nils; Sebastian, Tim (2023). Coagulation-monitored, dose-adjusted catheter-directed thrombolysis or pharmaco-mechanical thrombus removal in deep vein thrombosis. Vasa - European journal of vascular medicine, 52(6), pp. 416-422. Huber 10.1024/0301-1526/a001097
Barco, Stefano; Virdone, Saverio; Götschi, Andrea; Ageno, Walter; Arcelus, Juan I; Bingisser, Roland; Colucci, Giuseppe; Cools, Frank; Duerschmied, Daniel; Gibbs, Harry; Fumagalli, Riccardo M; Gerber, Bernhard; Haas, Sylvia; Himmelreich, Jelle C L; Hobbs, Richard; Hobohm, Lukas; Jacobson, Barry; Kayani, Gloria; Lopes, Renato D; MacCallum, Peter; ... (2023). Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials. Thrombosis research, 230, pp. 27-32. Elsevier 10.1016/j.thromres.2023.08.009
Voci, Davide; Fedeli, Ugo; Valerio, Luca; Schievano, Elena; Righini, Marc; Kucher, Nils; Spirk, David; Barco, Stefano (2023). Mortality rate related to peripheral arterial disease: A retrospective analysis of epidemiological data (years 2008-2019). Nutrition, metabolism, and cardiovascular diseases : NMCD, 33(3), pp. 516-522. Elsevier 10.1016/j.numecd.2022.11.020
Voci, Davide; Götschi, Andrea; Held, Ulrike; Bingisser, Roland; Colucci, Giuseppe; Duerschmied, Daniel; Fumagalli, Riccardo M; Gerber, Bernhard; Hasse, Barbara; Keller, Dagmar I; Konstantinides, Stavros V; Mach, François; Rampini, Silvana K; Righini, Marc; Robert-Ebadi, Helia; Rosemann, Thomas; Roth-Zetzsche, Stéphanie; Sebastian, Tim; Simon, Noemi R; Spirk, David; ... (2023). Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. Thrombosis research, 221, pp. 157-163. Elsevier 10.1016/j.thromres.2022.10.021
Wenger, Nicolas; Sebastian, Tim; Beer, Jürg H; Mazzolai, Lucia; Aujesky, Drahomir; Hayoz, Daniel; Engelberger, Rolf P; Korte, Wolfgang; Voci, Davide; Kucher, Nils; Barco, Stefano; Spirk, David (2022). Differences in duration of anticoagulation after pulmonary embolism and deep vein thrombosis: Findings from the SWIss Venous ThromboEmbolism Registry (SWIVTER). Thrombosis research, 220, pp. 65-71. Elsevier 10.1016/j.thromres.2022.10.006
Wolf, Simon; Spirk, David; Forgo, Gabor; Sebastian, Tim; Voci, Davide; Kucher, Nils; Barco, Stefano (2022). Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty. Vasa : European journal of vascular medicine, 51(6), pp. 357-364. Hogrefe 10.1024/0301-1526/a001025
Barco, Stefano; Voci, Davide; Held, Ulrike; Sebastian, Tim; Bingisser, Roland; Colucci, Giuseppe; Duerschmied, Daniel; Frenk, André; Gerber, Bernhard; Götschi, Andrea; Konstantinides, Stavros V; Mach, François; Robert-Ebadi, Helia; Rosemann, Thomas; Simon, Noemi R; Spechbach, Hervé; Spirk, David; Stortecky, Stefan; Vaisnora, Lukas; Righini, Marc; ... (2022). Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. Haematology, 9(8), e585-e593. Elsevier 10.1016/S2352-3026(22)00175-2
